Close Menu

NEW YORK (GenomeWeb) – After completing its first quarter as a public company, Salt Lake City, Utah-based Co-Diagnostics on Wednesday reported Q3 revenues of $2,598 compared to no revenue in the prior-year quarter.

For the three-month period ended Sept. 30, the firm's net loss grew to $3.9 million, or $.33 per share, from a loss of $449,950, or $.05 per share, in Q3 2016.

The firm's R&D expenses for the quarter rose 58 percent to $272,209 from $172,804 in Q3 2016, while SG&A expenses grew sevenfold to $1.5 million from $212,253.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.